Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × NSCLC × Drug Therapy × Clear all

Phase

Phase 2 4 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 16 Pancreatic Neoplasms 12 Colorectal Neoplasms 9 Breast Neoplasms 8 Rectal Neoplasms 7 Stomach Neoplasms 5 Neoplasm Metastasis 5 Recurrence 4 Ovarian Neoplasms 4 Neoplasms 4 Lung Neoplasms 4 Uterine Cervical Neoplasms 3 Prostatic Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Colonic Neoplasms 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Treatment 2 Solid Tumor 2 Small Cell Lung Cancer Limited Stage 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Glioma 2 Glioblastoma 2 Esophageal Neoplasms 2 Drug-Related Side Effects and Adverse Reactions 2 Waldenstrom Macroglobulinemia 1

Interventions

sugemalimab 1 spartalizumab 1 Vinorelbine 1 Radiotherapy 1 Pemetrexed 1 Paclitaxel 1 Liquid Biopsy 1 Gemcitabine 1 Gefitinib 1 Erlotinib Hydrochloride 1 Drug Therapy 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Peking Union Medical College

Phase NA Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡